CTIC - Cell Therapeutics Inc - Page 299

contrarian is one thing, but this is suicide

u're probably right.. but it's too late for me..

I've put a lot $$$ in already

If it does spike at all, get OUT!!

This company s/b filing bankruptcy any day now............

Shareholder Class Action Filed Against Cell Therapeutics, Inc.

by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP March 31, 2010 8:56 PM ET

Shareholder Class Action Filed Against Cell Therapeutics, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLPAnthem Blue Cross and Blue Shield and the Hospital of Saint Raphael Renew Network Agreement
All PR Newswire newsShareholder Class Action Filed Against Cell Therapeutics, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLPPR Newswire


RADNOR, Pa., March 31 /PRNewswire/ -- The following statement was issued today by the law firm of Barroway Topaz Kessler Meltzer & Check, LLP:

Notice is hereby given that a class action lawsuit was filed in the United States District Court for the Western District of Washington on behalf of purchasers of the securities of Cell Therapeutics, Inc. CTIC ("Cell Therapeutics" or the "Company"), who purchased or otherwise acquired Cell Therapeutics' securities between May 5, 2009 and March 19, 2010, inclusive (the "Class Period"), including purchasers of the securities issued pursuant or traceable to the Company's public offering on or about July 23, 2009.

If you wish to discuss this action or have any questions concerning this notice or your rights or interests with respect to these matters, please contact Barroway Topaz Kessler Meltzer & Check, LLP (Darren J. Check, Esq. or David M. Promisloff, Esq.) toll free at 1-888-299-7706 or 1-610-667-7706, or via e-mail at info@btkmc.com.

The Complaint charges Cell Therapeutics and certain of its officers and directors with violations of the Securities Act of 1933 and Securities Exchange Act of 1934. Cell Therapeutics is a biopharmaceutical company focused on developing and commercializing novel agents that seek to improve the safety and efficacy of existing standard-of-care chemotherapies, and those that may have unique, new mechanisms to kill cancer cells. During the Class Period, defendants misled investors concerning the results of a Phase III clinical study ("PIX-301") of a drug the Company was developing called pixantrone for the treatment of Non-Hodgkin's Lymphoma ("NHL"), as well as other cancers.

More specifically, the Complaint alleges that the Company failed to disclose and misrepresented the following material adverse facts which were known to defendants or recklessly disregarded by them: (1) the Company's Special Protocol Assessment for pixantrone was invalidated by the fact that the study was terminated before fully enrolled and a planned interim analysis was not conducted; (2) the FDA had not approved the early termination of Study PIX-301 or the statistical analysis defendants intended to apply to the results of the study; (3) the Company enrolled large numbers of patients who didn't suffer aggressive NHL as the study protocol required; and (4) patients taking pixantrone in Study PIX-301 suffered more deaths, serious adverse events, and grade 3-4 adverse events than patients taking the comparator drug, including three deaths from heart failure in the pixantrone group compared to one in the comparator group.

Plaintiff seeks to recover damages on behalf of class members and is represented by the law firm of Barroway Topaz Kessler Meltzer & Check which prosecutes class actions in both state and federal courts throughout the country. Barroway Topaz Kessler Meltzer & Check is a driving force behind corporate governance reform, and has recovered billions of dollars on behalf of institutional and individual investors from the United States and around the world.

For more information about Barroway Topaz Kessler Meltzer & Check, or for additional information about participating in this action, please visit www.btkmc.com.

If you are a member of the class described above, you may, not later than May 11, 2010, move the Court to serve as lead plaintiff of the class, if you so choose. A lead plaintiff is a representative party that acts on behalf of other class members in directing the litigation. In order to be appointed lead plaintiff, the Court must determine that the class member's claim is typical of the claims of other class members, and that the class member will adequately represent the class. Your ability to share in any recovery is not, however, affected by the decision whether or not to serve as a lead plaintiff. Any member of the purported class may move the court to serve as lead plaintiff through counsel of their choice, or may choose to do nothing and remain an absent class member.

^ Meh...not that big of a surprise. Almost always happens when a stock tanks.

Get out whilst you can IMO.. The writing is on the wall..

Did you manage to get out? At least get out with something in your hands. You're not a captain of a ship and have to go down with it...geez.

Read this:

The End Is Near for Cell Therapeutics

http://www.thestreet.com/story/10710...rapeutics.html

Is the market not open today? Also am I reading this right? Bid of 0.40?

CLOSED TODAY.

Good for CTIC, can't go down anymore today.

I logged on this morning to find the bid price through CTIC at $5.35 I was just waiting for it to open to hit the sell button.....
Someone must have fat fingered it. It corrected just a minute ago.

Well I'm out for good with this. Took another small loss, but I wrecked my car last week and had to pull my money out to put down on a new car. Best of luck to everyone that's still playing with this.....

CTIC chart

Good morning,

Here are some quick thoughts on the CTIC chart. After a quick fall a few weeks ago it appears CTIC may be nearing a bottom or interest level at the .40 cent price levels. Check out the OBV here and you will notice it is wanting to move up and cross the twenty EMA line. This could lead to an increase in price and a test of the .60 cent levels once again. Top levels of resistance I think are around .80 cents right now.

~Chart Analyzer

Have you been following this one? I wouldn't touch it with a 10 foot pole with a 20 foot extension...but that's just IMHO...

CTIC nice day

You have to really love a 10% day that took no effort. Let's see if this can continue tomorrow to test the .65 to .70 cent levels.

~Chart Analyzer

"2:05 AM ET 4/9/10 | Briefing.com
Co announces that it had received a Complete Response Letter from the FDA regarding its New Drug Application for Pixuvri for relapsed or refractory aggressive non-Hodgkin's lymphoma. The FDA cited as its primary reason for the action its concerns previously raised at the Oncologic Drugs Advisory Committee meeting on March 22, 2010 and recommended the co conduct an additional trial to demonstrate the safety and effectiveness of its product. Based on the FDA's ODAC presentation, which provided the Committee and the co with alternative options to consider to make investigational drugs available to patients if drugs need to be studied further prior to approval, the co has decided to pursue expanded access program for pixantrone while it conducts an additional study in aggressive NHL. "


I wish someone would just shoot me in the foot before i do it myself. Is it just me or does anyone else feel like Charlie Brown trying to kick a field goal? These little teasers keep coming out from CTIC (Lucy) it looks enticing, maybe THIS TIME I can actually kick that friggin ball. Then, the FDA comes in and jerks the football out at the last second becuase pixatrone has to severe side effects.

Quiting CTIC is like trying to quit smoking, it feels soo good, yet I know its going to kill me eventually.

conference call sounded good.

they are going to sue Adam f. from thestreet.com

volume increased dramatically from yesterday